Acadia Pharmaceuticals Inc [ACAD] stock is trading at $25.90, up 4.52%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ACAD shares have gain 3.15% over the last week, with a monthly amount drifted -4.67%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 21, February 2024, Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). In a post published today on Yahoo Finance, Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on February 15, 2024, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 111,823 shares of common stock and 34,087 restricted stock units (“RSUs”) to seventeen new employees under Acadia’s 2023 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
From an analyst’s perspective:
Acadia Pharmaceuticals Inc [NASDAQ: ACAD] stock has seen the most recent analyst activity on January 30, 2024, when Robert W. Baird initiated its Outperform rating and assigned the stock a price target of $40. Previously, Needham upgraded its rating to Buy on January 24, 2024, and kept the price target unchanged to $37. On December 19, 2023, upgrade upgraded it’s rating to Overweight and revised its price target to $40 on the stock. Deutsche Bank downgraded its rating to a Hold but stick to its price target of $25 on December 14, 2023. Citigroup initiated its recommendation with a Buy and recommended $38 as its price target on December 13, 2023. Deutsche Bank started tracking with a Buy rating for this stock on December 12, 2023, and assigned it a price target of $25. In a note dated November 06, 2023, Mizuho upgraded an Buy rating on this stock and boosted its target price from $20 to $35.
Acadia Pharmaceuticals Inc [ACAD] stock has fluctuated between $17.71 and $33.99 over the past year. Currently, Wall Street analysts expect the stock to reach $24.56 within the next 12 months. Acadia Pharmaceuticals Inc [NASDAQ: ACAD] shares were valued at $25.90 at the most recent close of the market. An investor can expect a potential drop of -5.17% based on the average ACAD price forecast.
Analyzing the ACAD fundamentals
Acadia Pharmaceuticals Inc [NASDAQ:ACAD] reported sales of 631.89M for the trailing twelve months, which represents a growth of 61.96%. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 25.04 points at the first support level, and at 24.17 for the second support level. However, for the 1st resistance point, the stock is sitting at 26.37, and for the 2nd resistance point, it is at 26.83.
Acadia Pharmaceuticals Inc [ACAD] reported earnings per share of -$0.4 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.43/share, meaning a difference of $0.03 and a surprise factor of 7.00%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were $0.01 per share as compared to estimates of -$0.08 per share, a difference of $0.09 representing a surprise of 112.50%.
Ratios To Look Out For
For context, Acadia Pharmaceuticals Inc’s Current Ratio is 2.38. Further, the Quick Ratio stands at 2.28, while the Cash Ratio is 0.05. Considering the valuation of this stock, the price to sales ratio is 6.73, the price to book ratio is 11.73.
Transactions by insiders
Recent insider trading involved DAVIS STEPHEN, CEO, that happened on Jan 08 when 3732.0 shares were sold. EVP, COO, Head of Commercial, Teehan Brendan completed a deal on Jan 08 to sell 731.0 shares. Meanwhile, EVP,General Counsel, Secretary KIM AUSTIN D. sold 590.0 shares on Jan 08.
